RPID
Rapid Micro Biosystems, Inc.
RPID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
RPID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RPID's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
RPID PE Valuation
RPID has no meaningful PE right now: it lost money over the past year.
RPID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect RPID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
RPID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.10 | -$0.09 |
| Q1 2026 | -$1.10 | -$0.07 |
| Q4 2025 | -$1.05 | +$0.03 |
| Q3 2025 | -$1.01 | +$0.11 |
| Q2 2025 | -$1.01 | +$0.16 |
| Q1 2025 | -$1.03 | +$0.18 |
| Q4 2024 | -$1.08 | +$0.14 |
| Q3 2024 | -$1.12 | +$0.23 |
RPID is still losing money, but less than at its worst: $1.10 per share over the past year, against $1.62 at its worst in early 2021.
RPID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.1M | +11% |
| Q1 2026 | $8M | +11% |
| Q4 2025 | $11.3M | +37% |
| Q3 2025 | $7.8M | +3.1% |
| Q2 2025 | $7.3M | +9.7% |
| Q1 2025 | $7.2M | +28% |
| Q4 2024 | $8.2M | +30% |
| Q3 2024 | $7.6M | +24% |
RPID's revenue has grown year over year for 14 quarters in a row: $8M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -153% | +14 points |
| Q1 2026 | -173% | -11 points |
| Q4 2025 | -108% | +16 points |
| Q3 2025 | -145% | +13 points |
| Q2 2025 | -167% | +35 points |
| Q1 2025 | -162% | +93 points |
| Q4 2024 | -124% | +68 points |
| Q3 2024 | -158% | +77 points |
RPID's operating margin was −153% last quarter, up 14 points from the same quarter a year ago.
RPID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12.5M | -$2.4M |
| Q1 2026 | -$15.5M | -$6.1M |
| Q4 2025 | -$3.3M | +$6.7M |
| Q3 2025 | -$9.1M | -$301K |
| Q2 2025 | -$10.1M | +$512K |
| Q1 2025 | -$9.4M | +$6.7M |
| Q4 2024 | -$10M | -$92K |
| Q3 2024 | -$8.8M | +$1.3M |
RPID has burned cash in almost every quarter: −$40M over the past year, against −$38M the year before.
RPID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.4% | +2.9M shares |
| 1 year | +8.3% | +3.7M shares |
| 3 years | +12% | +5.3M shares |
| 5 years | +52% | +16.6M shares |
RPID has 48M diluted shares, up 8.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RPID Net Leverage
RPID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RPID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.6 | Oversold |
| Stochastic | 4.6 | Oversold |
RPID's weekly RSI is 25 (oversold) and its Stochastic is 5 (oversold).
RPID PE vs Healthcare Sector
RPID has no meaningful PE right now: it lost money over the past year.
RPID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.81 | 17% below |
| 20 week MA | $1.34 | 50% below |
| 50 week MA | $2.29 | 71% below |
| 100 week MA | $2.57 | 74% below |
| 200 week MA | $1.78 | 62% below |
RPID is in a downtrend: it's below all five of its weekly moving averages, and 62% below its 200-week average.
RPID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.1 | $11.3 | -53% |
| 2022 | $11.3 | $1.43 | -87% |
| 2023 | $1.43 | $0.74 | -48% |
| 2024 | $0.74 | $0.96 | +30% |
| 2025 | $0.96 | $2.98 | +210% |
| 2026 YTD | $2.98 | $0.67 | -78% |
RPID's yearly returns have swung widely, from +210% in 2025 to −87% in 2022. It's down 78% so far in 2026.